These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

373 related articles for article (PubMed ID: 30190105)

  • 1. Healthcare burden of recurrent Clostridioides difficile infection in Japan: A retrospective database study.
    Kunishima H; Ito K; Laurent T; Abe M
    J Infect Chemother; 2018 Nov; 24(11):892-901. PubMed ID: 30190105
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictors and burden of hospital readmission with recurrent Clostridioides difficile infection: a French nation-wide inception cohort study.
    Dinh A; Le Monnier A; Emery C; Alami S; Torreton É; Duburcq A; Barbier F
    Eur J Clin Microbiol Infect Dis; 2019 Jul; 38(7):1297-1305. PubMed ID: 30941532
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Attributable Healthcare Resource Utilization and Costs for Patients With Primary and Recurrent Clostridium difficile Infection in the United States.
    Zhang D; Prabhu VS; Marcella SW
    Clin Infect Dis; 2018 Apr; 66(9):1326-1332. PubMed ID: 29360950
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of recurrent Clostridium difficile infection: hospitalization and patient quality of life.
    Wilcox MH; Ahir H; Coia JE; Dodgson A; Hopkins S; Llewelyn MJ; Settle C; Mclain-Smith S; Marcella SW
    J Antimicrob Chemother; 2017 Sep; 72(9):2647-2656. PubMed ID: 28633368
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization and risk factors for recurrence of Clostridioides (Clostridium) difficile infection in Japan: A nationwide real-world analysis using a large hospital-based administrative dataset.
    Kimura T; Snijder R; Sugitani T
    J Infect Chemother; 2019 Aug; 25(8):615-620. PubMed ID: 30987950
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence of and risk factors for recurrent Clostridioidesdifficile infection in Japan using a claims database: A retrospective cohort study.
    Mikamo H; Kondo T; Okuyama K; Marcella SW; Ruzicka DJ
    Anaerobe; 2020 Feb; 61():102139. PubMed ID: 31830597
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Healthcare resource utilization and direct medical costs associated with index and recurrent
    Feuerstadt P; Stong L; Dahdal DN; Sacks N; Lang K; Nelson WW
    J Med Econ; 2020 Jun; 23(6):603-609. PubMed ID: 31999199
    [No Abstract]   [Full Text] [Related]  

  • 8. Cost burden of Clostridioides difficile infection to the health service: A retrospective cohort study in Scotland.
    Robertson C; Pan J; Kavanagh K; Ford I; McCowan C; Bennie M; Marwick C; Leanord A
    J Hosp Infect; 2020 Nov; 106(3):554-561. PubMed ID: 32717202
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Comprehensive Study of Costs Associated With Recurrent Clostridium difficile Infection.
    Rodrigues R; Barber GE; Ananthakrishnan AN
    Infect Control Hosp Epidemiol; 2017 Feb; 38(2):196-202. PubMed ID: 27817758
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Excess length of hospital stay, mortality and cost attributable to
    Kimura T; Stanhope S; Sugitani T
    Epidemiol Infect; 2020 Mar; 148():e65. PubMed ID: 32115019
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Economic burden of recurrent Clostridioides difficile infection in adults admitted to Spanish hospitals. A multicentre retrospective observational study.
    Bouza E; Cobo J; Rodríguez-Hernández MJ; Salavert M; Horcajada JP; Iribarren JA; Obi E; Lozano V; Maratia S; Cuesta M; Uría E; Limón E
    Rev Esp Quimioter; 2021 Apr; 34(2):126-135. PubMed ID: 33618513
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clostridioides (Clostridium) difficile infection in Japanese hospitals 2008-2017: A real-world nationwide analysis of treatment pattern, incidence and testing density.
    Kimura T; Stanhope S; Sugitani T
    J Infect Chemother; 2020 May; 26(5):438-443. PubMed ID: 32081648
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk factors for recurrent Clostridium difficile infection (CDI) hospitalization among hospitalized patients with an initial CDI episode: a retrospective cohort study.
    Zilberberg MD; Reske K; Olsen M; Yan Y; Dubberke ER
    BMC Infect Dis; 2014 Jun; 14():306. PubMed ID: 24898123
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Burden of Clostridium (Clostridioides) difficile infection during inpatient stays in the USA between 2012 and 2016.
    Mollard S; Lurienne L; Heimann SM; Bandinelli PA
    J Hosp Infect; 2019 Jun; 102(2):135-140. PubMed ID: 30690052
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Economic burden of primary compared with recurrent Clostridium difficile infection in hospitalized patients: a prospective cohort study.
    Shah DN; Aitken SL; Barragan LF; Bozorgui S; Goddu S; Navarro ME; Xie Y; DuPont HL; Garey KW
    J Hosp Infect; 2016 Jul; 93(3):286-9. PubMed ID: 27209056
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hospitalization stay and costs attributable to Clostridium difficile infection: a critical review.
    Gabriel L; Beriot-Mathiot A
    J Hosp Infect; 2014 Sep; 88(1):12-21. PubMed ID: 24996516
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recurrent Clostridium difficile infection in intensive care unit patients.
    Jasiak NM; Alaniz C; Rao K; Veltman K; Nagel JL
    Am J Infect Control; 2016 Jan; 44(1):36-40. PubMed ID: 26432184
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inpatient Expenditures Attributable to Hospital-Onset Clostridium difficile Infection: A Nationwide Case-Control Study in Japan.
    Fukuda H; Yano T; Shimono N
    Pharmacoeconomics; 2018 Nov; 36(11):1367-1376. PubMed ID: 30022364
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clostridioides difficile infection in immunocompromised hospitalized patients is associated with a high recurrence rate.
    Avni T; Babitch T; Ben-Zvi H; Hijazi R; Ayada G; Atamna A; Bishara J
    Int J Infect Dis; 2020 Jan; 90():237-242. PubMed ID: 31672656
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Attributable costs and length of stay of hospital-acquired
    Leal JR; Conly J; Weaver R; Wick J; Henderson EA; Manns B; Ronksley P
    Infect Control Hosp Epidemiol; 2019 Oct; 40(10):1135-1143. PubMed ID: 31342884
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.